The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verifi ed Alzheimer's disease (AD). 
INTRODUCTION
Dementia disorders including Alzheimer's disease (AD) is one of the major public health concerns because of population aging ( 1, 2 ) . Th e number of individuals aff ected (35.6 million in 2011) is estimated to double every 20 years in the coming decades. Dementia results in decline in cognitive and functional abilities leading to dependence of help provided by other people and, consequently, substantial health-care costs ( 3 ) . Th us, investigation of potentially modifi able risk factors for dementia and AD is urgently needed.
Drug use may represent such modifi able risk factor, and several drugs have been associated with risk of dementia or AD. Some of them, such as benzodiazepines and related drugs ( 4-7 ) or anticholinergic drugs ( 8 ) , have potential direct links to the condition. Recently, another drug group, with perhaps less direct link to cognition, namely proton pump inhibitor (PPI) use, was associated with an increased risk of incident dementia (hazard ratio 1.44, 95% confi dence interval (CI) 1.36-1.52) in a German claims database ( 9 ) and in a German cohort study ( 10 ) . Th e association between PPIs and AD is based on results from cellular and animal models suggesting that lansoprazole may enhance production of amyloid-β ( 11 ) and accumulation of amyloid-β is an essential event in the pathogenesis of AD. Another mechanism hypothesized is that PPIs also inhibit vacuolar proton pumps (V-ATPases) on microglial lysosomes that leads to less acidic lysosomes and their reduced capability to degrade fi brillar amyloid-β , a degradation product of amyloid-β ( 12 ) .
Th e objective of our study was to investigate whether PPI use is associated with an increased risk of incident, clinically verifi ed AD in a Finnish nationwide nested case-control study. In addition to
No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease comparing the risk between users and nonusers, we investigated the dose-response relationship and the association between specifi c PPIs and AD risk.
METHODS
Th e MEDALZ study includes all community-dwelling individuals diagnosed with AD during 2005-2011 in Finland ( N =70,718) . For a nested case-control design, up to four matched comparison individuals were identifi ed for each case ( N =282,858) ( 13 ) .
Data sources
Data were extracted from Finnish nationwide health-care registers, including Special Reimbursement Register, Prescription Register, Hospital Discharge Register, and the censuses maintained by Statistics Finland. Th ese registers have been described in detail previously ( 14 ) . Each resident is assigned a unique social security number that was utilized to link data from these registers. Th e linkage was conducted by the Social Insurance Institution of Finland (SII). In Finland, all citizens/residents are covered by taxsupported public health-care service and have unrestricted access to health-care services, regardless of their socioeconomic status.
All data were de-identifi ed before submission to the research team and therefore ethics committee approval was not required according to Finnish legislation.
AD cases
Th e Finnish Clinical Care Guideline for cognitive disorders recommends that all individuals with suspected cognitive problems should be referred to specialist care, and if diagnosis is confi rmed to be AD, use of antidementia drugs should be initiated if there is no contraindication for use ( 15 ) . Th e diagnostic process is conducted according to a predefi ned protocol that includes computed tomography or magnetic resonance imaging scan and is based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) ( 16 ) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria. Certifi cate of the fulfi llment of the diagnostic criteria confi rmed by a geriatrician or neurologist is sent for evaluation to the SII that grants special reimbursement if criteria are fulfi lled. Th e diagnoses of AD is recorded in the Special Reimbursement register from which they were identifi ed for this study. All AD diagnoses in the MEDALZ cohort were made during between January 2005 and December 2011.
Controls
For each AD case, up to four age-, sex-, and region of residence (hospital district)-matched controls were identifi ed from a register including all residents, maintained by the SII. Criteria for comparison individuals were that they did not have diagnoses of AD or antidementia drug purchases for 1 year aft er being selected as controls. Aft er this, controls may become cases and four controls are matched for them as described. Controls were matched on the date of AD diagnoses that is referred as index date.
Exposure
Use of PPIs was defi ned according to ATC (Anatomical Th erapeutic Chemical-classifi cation system) ( 17 ) as A02BC. PPI use was extracted from Prescription register since 1995 (the beginning of the register) and until the index date. Th e Prescription register includes purchases of reimbursed drugs that were modeled with PRE2DUP method ( 18 ) to drug use periods, i.e., when drug use started and ended for each individual and for each drug. Drug use periods were constructed according to individual purchase histories and taking account on variation in purchase events. Th e method takes into account on stockpiling of drugs and periods in hospital care when drug use is not recorded in the register. Th e modeling is based on sliding averages of daily dose in defi ned daily doses (DDDs) ( 19 ) . For this study, drug use periods of each PPI drug substance were combined to retrieve duration of "any PPI use. " For each individual, cumulative duration of any PPI use were summed together from the observation period that started on 1995 and continued until the index date (in analyses without a lag window) or until the beginning of the lag window. For each individual, we also calculated cumulative PPI dose divided by the follow-up time by dividing cumulative dose in DDDs from all PPIs used during the observation period by cumulative duration of any PPI use. Th e reference DDD values for drugs used by the study cohort were: esomeprazole 30 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg ( 17 ).
Lag windows
Because of long latency for AD to develop and to account for reverse causality (i.e., AD or its prodromal symptoms aff ecting the PPI use), lag windows of 3 and 5 years were used in addition to analyses without any lag window (to represent what can occur without a lag). Th e lag window means that PPI use during a 3-or 5-year period before AD diagnoses was not considered in analyses, and all covariates were measured before the lag window. Time before the lag window is referred as observation period.
Covariates
Comorbid conditions were identifi ed from Special reimbursement (since 1972), Hospital discharge (since 1972), and Prescription register (since 1995). Th e Special reimbursement register includes data on individuals eligible for higher reimbursement of drugs because of certain chronic disease that are diagnosed according to predefi ned diagnostic protocol, as AD. Th e diagnoses can be made in inpatient or outpatient care. Hospital Discharge register includes data on hospital stays and discharge diagnoses reported by the attending physician according to ICD (International Classifi cation of Diseases) classifi cation. Comorbidities identifi ed from Special reimbursement register included cardiovascular diseases (any of the following conditions: hypertension, coronary artery disease, chronic heart failure, chronic arrhythmias) and diabetes. History of depression and stroke were identifi ed from hospitalizations. Comorbidities were measured as any diagnoses recorded during the observation period (since the beginning of the registers 1972) and this ensures the same follow-up time for case and his/ her controls as they are matched on the date of AD diagnoses STOMACH VOLUME 112 | DECEMBER 2017
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for the case. Th e number of any drugs used was calculated at the beginning of the lag window or at the index date when lag window was not utilized. Th e number of drugs was used as a proxy for comorbidity burden and categorized as 0, 1-4, 5-9, and ≥10.
Statistical analysis
Descriptive statistics were conducted with means (with s.d.), medians (with interquartile ranges), and χ 2 tests for categorical variables. Use of PPIs was compared between cases and controls.
Because of matched design, the association between PPI use and AD was investigated with conditional logistic regression with adjusting for covariates (cardiovascular disease, diabetes, history of depression, history of stroke, and number of drugs). Odds ratios (ORs) are represented with 95% confi dence intervals (CIs). Primary analyses compared any PPI use with no use. Duration of PPI use was categorized as <1, 1-3, and ≥3 years of use during the observation period and compared with no use. Use of ≥3 years is referred as long-term use. PPI dose was categorized as 0, 0.0001-0.4999, 0.5-0.9999, 1.0-1.4999, and ≥1.5 DDDs per day (0 being the reference category). All analyses were conducted with three-lag windows, i.e., no lag window (the follow-up until the index date) and 3-year and 5-year lag windows.
RESULTS
Median age of individuals with AD was 80.8 (interquartile range 76.1-84.9) years and was similar among individuals without AD (80.8, interquartile range 76.0-84.8) because of matched design. Th e number of drugs was higher in cases ( P <0.0001) and also comorbidities were more prevalent among individuals with AD compared with individuals without AD ( Table 1 ). Use of PPIs was frequent among both individuals with and without AD. With no lag window for PPI use, 44.1% of cases and 42.3% of controls used PPIs. With 5-year lag window, the prevalence of PPI use decreased to 26.2% of cases and 24.9% of controls. PPI users were older, more likely to be female, and more commonly had comorbidities and higher number of drugs compared with nonusers, both among individuals with and without AD ( Table 2 ) .
Any PPI use during the observation period was not associated with risk of AD ( Table 3 ). Although the ORs were suggestive of increased AD risk among PPI users, the diff erence in prevalence of PPI use between cases and controls was very small (<2%) and the CIs also included 1 in models without lag window and 3-year lag window. Th e results and the magnitude of absolute diff erence in exposure prevalence between cases and controls remained similar with 5-year lag window.
Long-term cumulative use was not consistently associated with AD. A protective association between long-term use and AD was observed in the model without lag window, but the association was abolished when a lag window was applied. Instead, <1 year of use was slightly associated with AD with all lag windows.
Th ere was no suggestion of dose-response relationship between cumulative dose divided by drug use time and AD ( Table 4 ) . Th e highest dose category was associated with higher risk of AD in the model without lag window, but this was no longer evident in models with 3-or 5-year lag window.
Th e second highest dose category (1-1.49) was associated with minor risk with all lag windows.
No specifi c PPI drug substance was signifi cantly associated with AD risk ( Table 5 ). Although lansoprazole was associated with slightly higher relative risk of AD in the lag window models, the absolute diff erence in the history of lansoprazole use between cases and controls was very small (<0.5%).
DISCUSSION
Contrary to the previous study ( 9 ), we did not fi nd clinically meaningful association between PPI use and AD. Even long-term PPI use (≥3 years) or the highest dose category (≥1.5 DDDs per day) were not associated with an increased risk when reverse causality was controlled by using 3-or 5-year lag window between exposure and outcome. Although there was some suggestion that <1 year of PPI use was related to higher relative risk of AD in comparison with nonusers, the diff erence in absolute prevalence was small. Furthermore, there was no evidence for a dose-response relationship. Th us, it is unlikely that the association between short-term use and AD refl ects causality.
Th ere are considerable diff erences between the study designs of this study and the German study ( 9 ) . In our study, the cases had clinically verifi ed AD diagnosis, whereas the German study assessed any dementia disorders recorded in the claims data. AD is the most common form of dementia accounting for 60-70% of the cases ( 2 ). Th us, it is likely that majority of dementia cases in the previous study had to be AD. However, as the proposed mechanisms found in cellular and animal models imply that PPIs would interfere amyloid-β degradation ( 11, 12 ) , one would expect that the potential association between PPIs and AD would be stronger when investigating specifi cally individuals with AD instead of any dementia disorders. Compared with previous study ( 9 ) our study included higher number of AD cases (70,718 compared with 29,510, respectively), resulting in larger number of PPI users. Th e present study was based on drug exposure modeled from data on purchased drugs. Purchase-based data are considered more valid source than data on drugs prescribed by a physician as it avoids primary nonadherence problem (i.e., drugs never bought from pharmacy) compared with prescribing information ( 20 ) . In addition, PPIs were not available as over-the-counter drugs during our study period with 3-and 5-year lag windows. Th us, exposure misclassifi cation in our study was minimized. Omeprazole was one of the most commonly used PPI in both this and previous study. Th us, the diff erent results are not explained by diff erences in utilized drug substances. Furthermore, none of the PPIs were associated with AD in drugspecifi c analyses.
We were also able to assess potential dose-response relationship between PPI use and risk of AD. Because AD has a long latency period, we controlled for possible reverse causality by inserting a lag window between PPI use and AD. Th e crucial impact of the lag period is most evident in dose analyses in which the highest dose category implies a higher risk when no lag window between exposure assessment and AD is applied but no risk is observed when a lag window of 3 or 5 years is applied. Similarly, the "protective" association of long-term use that was observed in the model without lag window was no longer evident when a lag window was applied. Th e lack of dose response in both dose and duration of use underline the lack of clinically meaningful association between PPI use and AD.
Th e strengths of our study include nationwide representativeness of all diagnosed AD cases. Th e Finnish health-care system and registers cover all citizens despite their socioeconomic position or age. AD diagnoses were clinically verifi ed according to international criteria. Because of the length of the follow-up, we were able to investigate the impact of lag window between exposure and outcome and to reduce possibility of reverse causality bias. Our drug use data were based on dispensed instead of prescribed drugs, and thus avoided primary nonadherence issue. All PPI drugs were reimbursed consistently during the observation period and not available over the counter. Furthermore, we utilized PRE2DUP method to model duration of drug use from drug purchases ( 18 ) . Th is, together with the dose analyses, enabled investigation of the impact of drug use patterns on AD risk.
Th e register-based nature of the data comprises some limitations. According to our national guidelines of care, the diagnosis of Taipale et al. 
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PPIs and Alzheimer's Disease AD should be made in early state ( 15 ) . However, we do not know whether AD was in early or moderate state at the time of diagnosis. Th at is why long lag time is needed in the analysis. Although the diagnosis of AD is mainly conducted in outpatient care, other diagnoses such as depression were available only from diagnoses recorded during the hospital stays and likely represents only the most severe cases. Register-based data also lack information on severity of the comorbid conditions. In addition, we were not able to take into account family history of AD as the data were not available in the registers. As our study is observational study, there is a possibility of residual confounding.
In conclusion, we found no consistent or clinically meaningful association between PPI use and risk of AD. Th e results for cumulative use were somewhat diff erent depending on the applied lag window. Some associations were statistically signifi cant but, given the results were not consistent, they are likely not clinically meaningful. Because the AD disease process goes on for several years before it can be diagnosed, it is essential to use a lag window in risk factor studies.
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